Reagents and instruments for immunology, cell biology and molecular biology.
 
> Exhibitions and events > Watch our webinars > Webinar: Advanced GMP Strategies for Cell Therapy Success

Webinar: Advanced GMP Strategies for Cell Therapy Success

  

  

Purpose and Scope

Overview

Growth factors and cytokines are vital in cell therapy manufacturing, driving the cell proliferation and differentiation needed for advanced therapeutic medicines. As therapies involving MSCs, iPSCs, CAR-T, and NK cells gain traction, the industry’s focus on stringent quality management is intensifying.
To ensure the safety and consistency of both final therapeutics and raw materials, advanced quality control measures and new assay validation procedures are becoming essential
 

This presentation explored:

                     
  Current Cell and gene therapy manufacturing workflows and bottlenecks       New innovative solutions towards product quality enhancement       Overview of Acro’s GMP production facility and capabilities  
                     

.
  Speaker  
 

Dr. Anil Kumar leads ACROBiosystems' efforts to support the clinical manufacturing of cell and gene therapies through advance GMP-grade products and solutions. Holding a PhD in Protein Engineering and bringing over a decade of expertise in biopharmaceutical R&D, Dr. Kumar has played a crucial role in steering teams and pushing forward the development of therapeutic modalities, particularly in immuno-oncology and autoimmune diseases.
Prior to joining ACROBiosystems, Dr. Kumar was the Director of Antibody Discovery and Protein Engineering at ImmunOs Therapeutics AG. During his tenure, he led his team in progressing multiple therapeutic approaches aimed at solid tumors, with the most significant achievement being the advancement of the lead biologic candidate, IOS-1002, toward clinical trials.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At ACROBiosystems, high-quality GMP-grade reagents are provided, which are critical for the clinical development of immune cell therapies, including CAR-T, NK cells, MSCs, and iPSCs. The cutting-edge 20,000-square-meter GMP production facility, coupled with a robust quality management system, meets the rigorous standards required for cell therapy drugs. A range of GMP-grade ancillary products is developed specifically to support the manufacturing of these therapies. These products undergo strict quality management and drug-level release testing to ensure their safety and efficacy, and are crafted to accelerate clinical research and streamline global regulatory approvals.